Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Hematology/Oncology Associates of Northern New Jersey, P.A.
mi
from
Morristown, NJ
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Hematology/Oncology Associates of Northern New Jersey, P.A.
mi
from
Morristown, NJ
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
North Shore Hematology Oncology Associates
mi
from
East Setauket, NY
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
North Shore Hematology Oncology Associates
mi
from
East Setauket, NY
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
mi
from
Dover, OH
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
mi
from
Dover, OH
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Toledo Clinical Cancer Center
mi
from
Toledo, OH
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Toledo Clinical Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Mercy Cancer Center at St. Anne's
mi
from
Toledo, OH
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Mercy Cancer Center at St. Anne's
mi
from
Toledo, OH
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Toledo Clinic Cancer Center-Toledo
mi
from
Toledo, OH
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Toledo Clinic Cancer Center-Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Upstate Oncology Associates
mi
from
Greenville, SC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Upstate Oncology Associates
mi
from
Greenville, SC
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
South Carolina Cancer Specialists
mi
from
Hardeeville, SC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
South Carolina Cancer Specialists
mi
from
Hardeeville, SC
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
South Carolina Cancer Specialists
mi
from
Hilton Head Island, SC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
South Carolina Cancer Specialists
mi
from
Hilton Head Island, SC
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Care Centers of South Texas-HOAST
mi
from
New Braunfels, TX
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Care Centers of South Texas-HOAST
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Care Centers of South Texas-HOAST
mi
from
San Antonio, TX
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Care Centers of South Texas-HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Blue Ridge Cancer Care
mi
from
Roanoke, VA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Blue Ridge Cancer Care
mi
from
Roanoke, VA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists
mi
from
Vancouver, WA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists
mi
from
Vancouver, WA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Green Bay Oncology
mi
from
Green Bay, WI
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Green Bay Oncology
mi
from
Green Bay, WI
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology-St. Mary's Hospital MC
mi
from
Green Bay, WI
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology-St. Mary's Hospital MC
mi
from
Green Bay, WI
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
mi
from
Innsbruck,
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
mi
from
Innsbruck,
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Clinical Oncology Program
mi
from
Saint Louis Park, MN
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Clinical Oncology Program
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota CCOP-Regions Hospital
mi
from
Saint Paul, MN
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota CCOP-Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
George Washington University Department of Medicine
mi
from
Washington,
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
George Washington University Department of Medicine
mi
from
Washington,
Click here to add this to my saved trials
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
Status: Enrolling
Updated:  12/31/1969
Georgetown Center for Functional And Molecular Imaging, Georgetown University Medical Center
mi
from
Washington,
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
Status: Enrolling
Updated: 12/31/1969
Georgetown Center for Functional And Molecular Imaging, Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
Status: Enrolling
Updated:  12/31/1969
Inova Heath Services Comprehensive Addictions Treatment Services (ICATS)
mi
from
Falls Church, VA
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults
Status: Enrolling
Updated: 12/31/1969
Inova Heath Services Comprehensive Addictions Treatment Services (ICATS)
mi
from
Falls Church, VA
Click here to add this to my saved trials
HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care
Status: Enrolling
Updated:  12/31/1969
Institute for Advanced Medicine, Mt. Sinai services
mi
from
New York, NY
HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care
Status: Enrolling
Updated: 12/31/1969
Institute for Advanced Medicine, Mt. Sinai services
mi
from
New York, NY
Click here to add this to my saved trials
HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care
Status: Enrolling
Updated:  12/31/1969
Mt Sinai Spencer Cox Center for Health
mi
from
New York, NY
HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care
Status: Enrolling
Updated: 12/31/1969
Mt Sinai Spencer Cox Center for Health
mi
from
New York, NY
Click here to add this to my saved trials
Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence
Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence
Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Status: Enrolling
Updated:  12/31/1969
Riley Child & Adolescent Psychiatry Clinic- Riley Hospital
mi
from
Indianapolis, IN
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Status: Enrolling
Updated: 12/31/1969
Riley Child & Adolescent Psychiatry Clinic- Riley Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Status: Enrolling
Updated:  12/31/1969
Lurie Center - MassGeneral Hospital
mi
from
Lexington, MA
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Status: Enrolling
Updated: 12/31/1969
Lurie Center - MassGeneral Hospital
mi
from
Lexington, MA
Click here to add this to my saved trials
Structural and Functional Neuroimaging Studies of Combat Veterans
Structural and Functional Neuroimaging Studies of Combat Veterans
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Structural and Functional Neuroimaging Studies of Combat Veterans
Structural and Functional Neuroimaging Studies of Combat Veterans
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Guided Self-Help for Binge Eating Disorder
Comparison of Integrative Response Therapy and Cognitive Behavioral Therapy Guided Self-Help for Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Guided Self-Help for Binge Eating Disorder
Comparison of Integrative Response Therapy and Cognitive Behavioral Therapy Guided Self-Help for Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
National Epidemiologic Survey on Alcohol and Related Conditions-III
National Epidemiologic Survey on Alcohol and Related Conditions -III
Status: Enrolling
Updated:  12/31/1969
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 9000 Rockville Pike
mi
from
Bethesda, MD
National Epidemiologic Survey on Alcohol and Related Conditions-III
National Epidemiologic Survey on Alcohol and Related Conditions -III
Status: Enrolling
Updated: 12/31/1969
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy
Status: Enrolling
Updated:  12/31/1969
South Texas Health Care System, San Antonio, TX
mi
from
San Antonio, TX
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy
Status: Enrolling
Updated: 12/31/1969
South Texas Health Care System, San Antonio, TX
mi
from
San Antonio, TX
Click here to add this to my saved trials
Changes in Sleep Patterns and Stress in Infants Entering Child Care
Changes in Sleep Patterns and Stress in Infants Entering Child Care: Implications for SIDS Risk
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Changes in Sleep Patterns and Stress in Infants Entering Child Care
Changes in Sleep Patterns and Stress in Infants Entering Child Care: Implications for SIDS Risk
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
University of California, Davis, M.I.N.D. Institute
mi
from
Sacramento, CA
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
University of California, Davis, M.I.N.D. Institute
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Neuropsychiatric Research Center of Orange County
mi
from
Santa Ana, CA
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Neuropsychiatric Research Center of Orange County
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Lake Mary Pediatrics
mi
from
Orange City, FL
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Lake Mary Pediatrics
mi
from
Orange City, FL
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Center for Psychiatric Research
mi
from
Hoffman Estates, IL
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Center for Psychiatric Research
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Louisiana State Univ.
mi
from
Shreveport, LA
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Louisiana State Univ.
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine
mi
from
Manhattan, NY
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine
mi
from
Manhattan, NY
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated:  12/31/1969
Oklahoma State University, Child Study Center
mi
from
Oklahoma City, OK
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase III Open Label Extension Study of CM-AT in Children With Autism
Status: Enrolling
Updated: 12/31/1969
Oklahoma State University, Child Study Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials